Tatjana Tissen‐Diabaté

Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors

Corinna Weber‐Schoendorfer, Angela Kayser, Tatjana Tissen‐Diabaté et al. · Journal of Hypertension · 2019 · 35 citations

Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database

Corinna Weber‐Schoendorfer, Evelin Beck, Tatjana Tissen‐Diabaté et al. · Reproductive Toxicology · 2017 · 29 citations

Drug Safety, Preclinical Drug Evaluation, Pharmacological Study +8

Safety of diclofenac use during early pregnancy: A prospective observational cohort study

Stephanie Padberg, Tatjana Tissen‐Diabaté, Katarina Dathe et al. · Reproductive Toxicology · 2018 · 22 citations

Maternal Complication, Clinical Epidemiology, Pediatrics +11

Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – Treatment or hypertension related? An observational cohort study

Maria Hoeltzenbein, Tatjana Tissen‐Diabaté, Anne‐Katrin Fietz et al. · Pregnancy Hypertension · 2018 · 22 citations

Hypertension, Cardiovascular Disease, First Trimester Use +13

Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study

Katarina Dathe, Stephanie Padberg, Stefanie Hultzsch et al. · European Journal of Clinical Pharmacology · 2017 · 21 citations

First Trimester, Cox-2 Inhibitors, Maternal Cardiovascular Outcome +12